Effect of Ganglioside combined with pramexol in the treatment of Parkinson's disease and its effect on motor function

Effect of Ganglioside combined with pramexol in the treatment of Parkinson's disease and its effect on motor function

Background: This study was aimed to evaluate the efficacy of pramipexole combined with ganglioside for PD treatment and pramipexole monotherapy, so as to provide reference for clinical practice. Methods: 61 PD patients selected from June 2019 to December 2020 at our hospital were divided into two gr...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Li Xinna, Han Peihai, Liu Mengjiao, Li Xiaowen, Xue Shuai
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	Society of Medical Biochemists of Serbia, Belgrade 2023-01-01
Sraith:	Journal of Medical Biochemistry
Ábhair:	pd gangliosides pramipexole motor function updrs
Rochtain ar líne:	https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2023/1452-82582303505L.pdf

Míreanna comhchosúla

Could vitamin D deficiency have an impact on motor and cognitive function in Parkinson’s disease?
de réir: Rasha H. Soliman, et al.
Foilsithe / Cruthaithe: (2019-05-01)

The Effects of Group Therapeutic Singing on Cortisol and Motor Symptoms in Persons With Parkinson's Disease
de réir: Elizabeth L. Stegemöller, et al.
Foilsithe / Cruthaithe: (2021-07-01)

Gangliosides in milk
de réir: Slavica Potočki, et al.
Foilsithe / Cruthaithe: (2016-07-01)

Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
de réir: Yoonjae Choi, et al.
Foilsithe / Cruthaithe: (2011-05-01)

Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
de réir: Yoonjae Choi, et al.
Foilsithe / Cruthaithe: (2010-10-01)

Profile in ganglioside antibodies in benign prostatic hyperplasia
de réir: Ilinca Nicolae, et al.
Foilsithe / Cruthaithe: (2016-03-01)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
de réir: Hametner EM, et al.
Foilsithe / Cruthaithe: (2012-03-01)

Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale
de réir: Priya Jagota, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Assessment of non-motor symptoms of Parkinson's disease and their impact on the quality of life: An observatiobnal study
de réir: Anand Kumar, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Role of gangliosides in prostate pathology
de réir: Ilinca Nicolae, et al.
Foilsithe / Cruthaithe: (2016-03-01)

Sleep disorders in Parkinson's disease
de réir: M. R. Nodel
Foilsithe / Cruthaithe: (2011-03-01)

NON-MOTOR VISUAL DISORDERS IN KAZAKHTAN PATIENTS WITH PARKINSON'S DISEASE
de réir: S. U. Kamenova, et al.
Foilsithe / Cruthaithe: (2021-12-01)

NON-MOTOR VISUAL DISORDERS IN KAZAKHTAN PATIENTS WITH PARKINSON'S DISEASE
de réir: S. U. Kamenova, et al.
Foilsithe / Cruthaithe: (2021-12-01)

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
de réir: Mylene Huebecker, et al.
Foilsithe / Cruthaithe: (2019-11-01)

Innovative Parkinson's Disease Patients' Motor Skills Assessment: The i-PROGNOSIS Paradigm
de réir: Sofia Balula Dias, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Effects of methylprednisolone and ganglioside GM-1 on a spinal lesion: a functional analysis
de réir: Márcio Oliveira Penna Carvalho, et al.
Foilsithe / Cruthaithe: (2008-01-01)

The Key Role of GM1 Ganglioside in Parkinson’s Disease
de réir: Suman Chowdhury, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism
de réir: ABHIJITH LALESH MERAJOTH, et al.
Foilsithe / Cruthaithe: (2016-05-01)

Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole
de réir: M. R. Nodel
Foilsithe / Cruthaithe: (2011-12-01)

Titration of serum anti-ganglioside antibodies in patients with chronic medular injury previous to treatment with GM1 ganglioside
de réir: Tarcísio Eloy Pessoa Barros Filho, et al.
Foilsithe / Cruthaithe: (2003-04-01)

Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices
de réir: Henrietta O. Fasanya, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Foot–Floor Contact Sequences: A Metric for Gait Assessment in Parkinson’s Disease after Deep Brain Stimulation
de réir: Marco Ghislieri, et al.
Foilsithe / Cruthaithe: (2024-10-01)

Gangliosides and the Treatment of Neurodegenerative Diseases: A Long Italian Tradition
de réir: Maria Fazzari, et al.
Foilsithe / Cruthaithe: (2022-02-01)

Clinical Evaluation in Parkinson’s Disease: Is the Golden Standard Shiny Enough?
de réir: Foivos S. Kanellos, et al.
Foilsithe / Cruthaithe: (2023-04-01)

Result of Pallidotomy in Parkinson’s Disease in Nepal
de réir: Resha Shrestha, et al.
Foilsithe / Cruthaithe: (2016-12-01)

The structure of gangliosides hides a code for determining neuronal functions
de réir: Giulia Lunghi, et al.
Foilsithe / Cruthaithe: (2021-12-01)

Anti-ganglioside antibodies alter presynaptic release and calcium influx
de réir: Brigitte Buchwald, et al.
Foilsithe / Cruthaithe: (2007-10-01)

Multi-dimensional role of gangliosides in modulating cancer hallmarks and their prospects in targeted cancer therapy
de réir: Abhisek Sarkar, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Simulating the enzymes of ganglioside biosynthesis with Glycologue
de réir: Andrew G. McDonald, et al.
Foilsithe / Cruthaithe: (2021-03-01)

Technologies for Assessment of Motor Disorders in Parkinson’s Disease: A Review
de réir: Qi Wei Oung, et al.
Foilsithe / Cruthaithe: (2015-08-01)

Effects of ganglioside G(M1) and erythropoietin on spinal cord lesions in rats: functional and histological evaluations
de réir: Raphael Martus Marcon, et al.

The Trajectory of Motor Deterioration to Death in Parkinson's Disease
de réir: Sabrina Poonja, et al.
Foilsithe / Cruthaithe: (2021-08-01)

Multi-Dimensional, Short-Timescale Quantification of Parkinson's Disease and Essential Tremor Motor Dysfunction
de réir: John B. Sanderson, et al.
Foilsithe / Cruthaithe: (2020-09-01)

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
de réir: Melanie Alpaugh, et al.
Foilsithe / Cruthaithe: (2017-10-01)

Gangliosides in subacute sclerosing leukoencephalitis: isolation and fatty acid composition of nine fractions
de réir: Robert Ledeen, et al.
Foilsithe / Cruthaithe: (1968-01-01)

Challenges in the Analysis of Gangliosides by LC-MS
de réir: Thomas Muggli, et al.
Foilsithe / Cruthaithe: (2022-02-01)

An Overview of Acoustic-Based Interventions to Improve Motor Symptoms in Parkinson’s Disease
de réir: Jessie Siew Pin Leuk, et al.
Foilsithe / Cruthaithe: (2020-08-01)

Editorial: Pharmacology of gangliosides
de réir: Hongda Zhuang, et al.
Foilsithe / Cruthaithe: (2024-07-01)

Motor networks, but also non-motor networks predict motor signs in Parkinson’s disease
de réir: Anjanibhargavi Ragothaman, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
de réir: Hauser RA, et al.
Foilsithe / Cruthaithe: (2018-03-01)